SPECT/CT study of bronchial deposition of inhaled particles. A human aerosol vaccination model against HPV.

Details

Ressource 1Download: 27440125AM.pdf (2598.55 [Ko])
State: Public
Version: Author's accepted manuscript
Serval ID
serval:BIB_727B0B817EDB
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
SPECT/CT study of bronchial deposition of inhaled particles. A human aerosol vaccination model against HPV.
Journal
Nuklearmedizin. Nuclear medicine
Author(s)
Ilic V., Dunet V., Le Pape A., Buchs M., Kosinski M., Bischof Delaloye A., Gerber S., Prior J.O.
ISSN
0029-5566 (Print)
ISSN-L
0029-5566
Publication state
Published
Issued date
26/09/2016
Peer-reviewed
Oui
Volume
55
Number
5
Pages
203-208
Language
english
Notes
Publication types: Controlled Clinical Trial ; Journal Article

Abstract
Vaccination by aerosol inhalation can be used to efficiently deliver antigen against HPV to mucosal tissue, which is particularly useful in developing countries (simplicity of administration, costs, no need for cold chain). For optimal immunological response, vaccine particles should preferentially be delivered to proximal bronchial airways. We aimed at quantifying the deposition of inhaled particles in central airways and peripheral lung, and to assess administration biosafety. Participants, methods: 20 healthy volunteers (13W/7M, aged 24±4y) performed a 10-min free-breathing inhalation of (99m)Tc-stannous chloride colloid aerosol (450 MBq) in a buffer solution without vaccinal particles using an ultrasonic nebulizer (mass median aerodynamic diameter 4.2 μm) and a double mask inside a biosafety cabinet dedicated to assess environmental particle release. SPECT/CT and whole-body planar scintigraphy were acquired to determine whole-body and regional C/P distribution ratio (central-to-peripheral pulmonary deposition counts). Using a phantom, SPECT sensitivity was calibrated to obtain absolute pulmonary activity deposited by inhalation.
All participants successfully performed the inhalation that was well tolerated (no change in pulmonary peak expiratory flow rate, p = 0.9). It was environmentally safe (no activity released in the biosafety filter.) 1.3±0.6% (range 0.4-2.6%) of the total nebulizer activity was deposited in the lungs with a C/P distribution ratio of 0.40±0.20 (range 0.15-1.14).
Quantification and regional distribution of inhaled particles in an aerosolized vaccine model is possible using radioactive particles. This will allow optimizing deposition parameters and determining the particles charge for active-particles vaccination.

Keywords
Administration, Inhalation, Adult, Aerosols/administration & dosage, Aerosols/pharmacokinetics, Bronchi/diagnostic imaging, Bronchi/metabolism, Female, Humans, Isotope Labeling, Male, Papillomavirus Infections/metabolism, Papillomavirus Infections/prevention & control, Papillomavirus Vaccines/administration & dosage, Papillomavirus Vaccines/pharmacokinetics, Radiopharmaceuticals/pharmacokinetics, Single Photon Emission Computed Tomography Computed Tomography/methods, Technetium/pharmacokinetics, Tissue Distribution, 99mTc, Aerosol inhalation, HPV, SPECT/CT, pulmonary deposition, targeted vaccine delivery
Pubmed
Web of science
Create date
30/07/2016 11:58
Last modification date
20/08/2019 14:30
Usage data